According to Bloomberg, the seven research firms now covering MorphoSys AG (NASDAQ: M.O.R.) have given the stock an average recommendation of “Hold” for its shareholders to consider. The research companies issued this recommendation to the shareholders of MorphoSys AG. Five market experts have assigned the stock a buy rating, and two of those five analysts have suggested that investors purchase the stock. Most analysts who have updated their firm coverage within the last twelve months have set a price objective of $28.40 on the stock, which is the average of all their price targets. In a separate research report issued on Friday, July 29th, Morgan Stanley raised their target price on MorphoSys shares from €26.00 ($26.53) to €28.00 ($28.57) in a separate research report. The firm also classified the company as “equal weight” in the independent research report. When trading started on Tuesday, the cost of a single share of MorphoSys common stock was $4.45. The company’s beta value is 1.18, and its P/E ratio is -0.63; both numbers are negative. The company’s total value, measured by its market capitalization, is $608.64 million.
The current ratio to quick ratio is 2.91, and the quick ratio to current balance is 2.98. The debt-to-equity ratio is 2.01, and the quick ratio to the current ratio is 2.91. The company’s moving average price over the previous 50 days is $5.35, and the moving average cost for the previous 200 days is $5.78. Over the last 52 weeks, MorphoSys stock’s highest and lowest price was $15.16. The most recent quarterly earnings report for MorphoSys (NASDAQ: M.O.R.) was made public on August 8th, a Monday. The company stated that its earnings per share (EPS) for the quarter came in at $1.72, which was $1.45 below the average expectation offered by analysts ($0.27). In addition, MorphoSys’ return on equity and net margin were in the red, with the former falling short by 345.89% and the latter falling short by 439.59%, respectively. During the same period the year before, the business posted earnings per share of $0.18. Sell-side analysts project that MorphoSys will have revenues of -2.39 cents per share in 2018, resulting in a loss for the company. The number of shares of the company’s stock that hedge funds and other institutional investors own has climbed due to recent purchases.
In the last three months of 2018, Candriam Luxembourg S.C.A. gained 1.9% in the proportion of MorphoSys shares it owned. Today, Candriam Luxembourg S.C.A. is the owner of the firm’s shares, which have a total value of $7,705,000; of these shares, 273,835 were purchased by the company. These shares were acquired in total. In the second quarter, Virtu Financial L.L.C. invested around $53,000 in MorphoSys, which allowed them to establish a new position in the company. During the first three months of the year, Capricorn Fund Managers Ltd. made a new investment in the company MorphoSys that was worth a total of $177,000. During the second quarter of the fiscal year, Old Mission Capital L.L.C. made a new investment for approximately 195,000 dollars in MorphoSys. Lastly, but by no means least, Optiver Investment B.V. put about 340,000 euros toward the purchase of a new stake in MorphoSys shares during the second quarter. One point eight percent of the total number of shares outstanding in the company are held by hedge funds and other institutional investors.
The biopharmaceutical business MorphoSys AG, with headquarters in the United States, is currently operating in the commercial stage of its product development. The company’s key focuses are the discovery, development, and eventual commercialization of therapeutic antibodies for patients suffering from autoimmune illnesses and cancer, which are the key focuses of the company. For example, Tafasitamab is an effective antibody in treating B-cell lymphomas like marginal zone lymphoma, follicular lymphoma and diffuse large B-cell lymphoma, among others.